Drug Profile
AM 0012
Alternative Names: AM0012Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator ARMO Biosciences
- Class Antineoplastics; Cytokines; Interleukins
- Mechanism of Action CD8 positive T lymphocyte stimulants; Interleukin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 22 Jun 2018 ARMO Biosciences has been acquired by Eli Lilly
- 29 Aug 2017 Preclinical trials in Cancer in USA (Parenteral) (ARMO Biosciences pipeline, August 2017)